Skip to main content

Table 2 Lung BAL cell differentials and protein

From: Impact of pulmonary exposure to gold core silver nanoparticles of different size and capping agents on cardiovascular injury

  % Macrophages % Neutrophils % Eosinophils % Lymphocytes % Epithelial Cells Protein (mg/mL)
1 Day       
 Citrate 96.0 ± 0.7 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 3.8 ± 0.7 0.2 ± 0.1
 20 nm AgNP 91.8 ± 1.2b 1.4 ± 1.3 0.4 ± 0.3 1.1 ± 0.3 5.3 ± 0.5 0.4 ± 0.1
 110 nm AgNP 91.1 ± 0.5b 0.6 ± 0.6 0.8 ± 0.4 0.3 ± 0.1 7.0 ± 0.3b 0.4 ± 0.0
 PVP 95.2 ± 0.9 0.1 ± 0.1 0.4 ± 0.3 0.8 ± 0.6 3.5 ± 0.5 0.6 ± 0.1
 20 nm AgNP 92.3 ± 0.9b 0.6 ± 0.1 0.3 ± 0.2 0.3 ± 0.2 6.4 ± 1.0 0.8 ± 0.1b
 110 nm AgNP 91.9 ± 0.8b 0.0 ± 0.0 0.4 ± 0.4 0.7 ± 0.2 7.0 ± 0.9 0.8 ± 0.1b
7 Day       
 Citrate 88.8 ± 4.7 0.4 ± 0.2 0.1 ± 0.1 1.1 ± 0.6 9.6 ± 4.3 0.2 ± 0.0
 20 nm AgNP 96.9 ± 0.9b 1.3 ± 1.0 0.2 ± 0.2 0.9 ± 0.4 0.7 ± 0.1b 0.3 ± 0.2
 110 nm AgNP 96.8 ± 1.4b 0.6 ± 0.3 0.1 ± 0.1 2.0 ± 0.9 0.5 ± 0.3b 0.2 ± 0.1
 PVP 95.3 ± 1.0 0.6 ± 0.3 0.1 ± 0.1 1.5 ± 0.6 2.5 ± 1.1 0.2 ± 0.0
 20 nm AgNP 90.7 ± 3.9 3.6 ± 2.7 0.2 ± 0.2 3.1 ± 2.3 2.5 ± 0.9 0.2 ± 0.0
 110 nm AgNP 94.2 ± 1.5 1.0 ± 0.5 0.3 ± 0.2 1.2 ± 0.6 3.3 ± 2.0 0.1 ± 0.0b,c
  1. Calculated percentage of total cell BALF pellet and protein quantification. bdenotes significant (p < 0.05) versus vehicle, cdenotes significance from other AgNP particle size within a capping agent, calculated by one-way ANOVA with Tukey Post Hoc test Values expressed mean ± SEM, n = 4–8